Corteva, Inc. (CTVA)

How it makes money

Revenue comes from two distinct product sales: branded seed with proprietary genetics and traits (Seed), and herbicides, insecticides and fungicides (Crop Protection). Both are booked when the dealer or farmer takes delivery, concentrated in the planting seasons of each hemisphere. Seed carries higher margins thanks to patented traits; Crop Protection is more exposed to generic competition once patents expire.

Revenue by segment

Corteva's germplasm library reflects roughly 90 years of Pioneer breeding and field-testing data, and it holds thousands of patents including its own biotech traits rather than relying only on licenses. That data and IP base is hard to replicate quickly, but Bayer and Syngenta hold comparable positions, so the advantage is real but not exclusive.

Purchases follow the planting calendar and farmers' expected income: commodity crop prices, input costs and weather in a given season decide how much a grower spends on seed and chemicals that year. A drought, a flood or a slump in corn and soybean prices can compress an entire season's demand quickly.

Key risks

• Dependence on regulatory approvals — New seed traits and crop-protection products need approval from agencies such as the EPA, USDA and FDA and their equivalents abroad, and countries' rules on genetically modified crops differ and can change, delaying or blocking launches.
• Weather and climate variability — Abnormal weather in a major growing region — drought, excess rain, early frost — reduces both the acreage planted and the demand for crop inputs in that season, and the company cannot offset a bad season with sales elsewhere in the same window.
• Legacy environmental and litigation liabilities — Corteva carries obligations and litigation exposure inherited from its DuPont and Chemours history, including PFAS-related claims and crop-protection product liability suits, which can result in material costs unrelated to current operating performance.
• Competition from generics and major peers — Once a crop-protection active ingredient's patent expires, generic manufacturers can undercut it on price, and Corteva competes across both segments against a small number of very large rivals with comparable scale and research budgets.
• Execution risk of the planned Seed and Crop Protection separation — In October 2025 Corteva announced a plan to split into two independent listed companies. Carrying out that separation involves cost, management distraction and uncertainty over how each resulting company's shared costs and liabilities will be divided.